Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 566,278 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 566,278 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16. Following the completion of the sale, the chief operating officer now directly owns 1,462,223 shares in the company, valued at approximately $16,406,142.06. The trade was a 27.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, June 2nd, Eric Venker sold 433,722 shares of Roivant Sciences stock. The shares were sold at an average price of $11.07, for a total value of $4,801,302.54.
• On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.95, for a total value of $1,095,000.00.
• On Monday, April 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00.
• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96.
• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32.

Roivant Sciences Trading Up 0.3%

Shares of Roivant Sciences stock traded up $0.03 during trading on Friday, reaching $11.23. The company's stock had a trading volume of 4,927,975 shares, compared to its average volume of 5,562,342. The stock has a 50-day moving average price of $10.61 and a two-hundred day moving average price of $11.02. The stock has a market capitalization of $8.01 billion, a P/E ratio of -74.86 and a beta of 1.16. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. The company had revenue of $7.57 million during the quarter, compared to analyst estimates of $62.17 million. During the same quarter in the previous year, the business posted ($0.23) EPS. As a group, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, May 28th.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in ROIV. FMR LLC lifted its stake in shares of Roivant Sciences by 0.3% in the 4th quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after purchasing an additional 156,527 shares during the period. Vanguard Group Inc. grew its stake in shares of Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after acquiring an additional 2,404,232 shares in the last quarter. Patient Square Capital LP grew its position in Roivant Sciences by 2.1% in the fourth quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after purchasing an additional 251,535 shares in the last quarter. Two Seas Capital LP increased its position in shares of Roivant Sciences by 4.6% in the fourth quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock valued at $120,285,000 after acquiring an additional 442,914 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Roivant Sciences by 3.8% in the first quarter. Invesco Ltd. now owns 9,880,526 shares of the company's stock valued at $99,695,000 after purchasing an additional 365,468 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.